Cellular Intelligence, a Mark Zuckerberg‑backed, AI‑native biotech, has acquired global rights to STEM‑PD, Novo Nordisk’s clinical‑stage cell‑therapy programme for Parkinson’s disease, the companies said. The therapy, an allogeneic, pluripotent stem‑cell‑derived dopaminergic progenitor product that aims to replace neurons lost in Parkinson’s, has completed early human testing and carries an FDA Fast Track designation. Under the agreement, Novo Nordisk will take an equity stake in Cellular Intelligence and will be eligible to receive future milestone payments and royalties, while Cellular Intelligence gains responsibility for further development and global commercialisation; financial terms were not disclosed.
Novo Nordisk previously wound down parts of its cell‑therapy operations as part of a restructuring that left STEM‑PD available for transfer, and the deal moves the programme to a small, AI‑focused company that says it will leverage proprietary machine‑learning tools to accelerate clinical development, optimise manufacturing scale‑up and reduce production costs. Cellular Intelligence and Novo said the arrangement will pair the programme’s academic and clinical foundation with the biotech’s AI capabilities to advance the therapy toward later‑stage trials.
Industry observers noted the transfer is notable because there are currently no approved cell therapies that restore dopamine‑producing neurons in Parkinson’s, making STEM‑PD a closely watched asset in regenerative neurology if development succeeds. Cellular Intelligence has indicated plans to push the programme into larger studies, and stakeholders will be watching for announcements about a Phase 2 start, manufacturing partnerships and any disclosed financial milestones or timelines.
The companies issued statements describing the strategic rationale but provided limited commercial detail; further updates are expected as Cellular Intelligence outlines development milestones and regulatory plans.
